20 abstracts highlight research in key disease areas including psoriasis and psoriatic arthritis New three-year data to be presented on bimekizumab in the treatment of moderate to severe plaque psoriasis BRUSSELS and ATLANTA, Sept. 1, 2022 /PRNewswire/ — UCB, a global biopharmaceutical…
